reason report
mix revenu profit outlook tweak estim remain
bottom line follow call remain posit though
lower earn estim reflect new
move slightli higher better volum trend revenu volum
trend posit believ investor disappoint
higher expect reinvest
slow earn growth guidanc howev mostli
expect buoy continu trend strong cold/
flu season pbm busi seem perform well
sell season end net new win client retent
rais revenu estim slightli reflect better volum
store trend lower earn estim higher op-ex
reduc pt remain op rate share
volum trend retail/long term care growth
rate total ss sale pharmaci ss sale pharmaci ss script
came ahead model volum growth good despit
headwind ss rx due restrict network known
furthermor compani retail pharmaci market share increas
bp y/i flu season help script volum decemb growth
rate also benefit lap impact restrict network
deal encouragingli manag said healthi script growth return
driven optum esrx collabor prefer
statu network model ss rx growth
vs guidanc overal result quarter good
view import metric view retail volum revenu
earn ahead model guid
retail also ahead previou expect
pbm sound healthi season report gross win
net new busi solid client retent rate
part total live manag increas
live season manag estim renew
includ fep retail mail contract estim worth also
specialti growth remain strong revenu y/i quarter
rx also increas benefit new product introduct
increas access limit distribut product sinc alreadi
aet client exist plan client may view cvs/aet deal
less risk client
net debt total capit
compani inform leerink partner llc research
revenu billion
adjust ep exclud acquisit amort one-tim item exclud interest expens relat aet transact exclud
revenu earn aet deal
pleas refer page import disclosur price chart analyst certif
guidanc mostli estim consolid net revenu
growth guid vs previou adj oper
profit growth expect y/i vs previou estim
y/i retail revenu expect y/i vs
previou estim like reflect strong flu season
pbm expect grow midpoint slightli
prior model oper profit growth look solid least
first quarter retail expect grow low mid-singl digit vs
previou estim pbm seen flattish slightli vs
previou estim
guidanc disappoint lower outlook adj
oper profit growth result sever op-ex invest
guidanc mean growth oper incom
midpoint vs prior last guid manag plan
spend area higher employe wage benefit invest
data analyt care manag solut invest
store pilot new servic offer total addit
oper expens mostli retail/ltc manag said run
rate view mean oper profit
lower previou expect well higher cost
disappoint estim invest made
prepar aet order maxim use clinic health
servic pharmaci need invest
metric mostli unchang guid
manag continu forecast total revenu growth
tax rate take account tax reform
decemb retail/ltc revenu remain same-stor
sale growth same-stor script growth
higher script growth refresh import view
oper profit growth retail/ltc low-singl digit
vs low-singl digit previous pbm revenu growth remain
total adjust claim oper
profit growth low mid-singl digit reduc oper incom
guidanc retail disappoint howev estim due
mainli higher invest go back busi
tweak estim revenu estim move
modestli reflect posit volum trend reduc earn
estim year reflect higher op-ex cost busi
mix market pressur pt result move
believ stand benefit brand gener convers pbm share gain growth
retail high growth rate specialti pharmaceut retail pharmaci
pbm believ differenti offer substanti buy power allow
compani price highli competit deliv high qualiti care uniqu cost-
save model mani plan sponsor seek narrow network consid one
best market -- preval expect increas next
year estim alreadi one largest retail chain countri expect
addit growth come open new pharmaci acquisit
independ pharmaci smaller chain next sever year expect gener
drug launch advent biosimilar remain industri trend help drive
margin expans believ minuteclin benefit grow emphasi
popul health manag expect see increment benefit sell
season express script optum continu streamlin oper integr new
custom win acquisit also posit propos cvs/aet combin
deal enabl live integr medic pharmaci benefit aet
live creat new sourc revenu earn
next month expect share trade ep
would put stock price target lower believ
deserv trade slight discount histor multipl given slowdown gener
launch calendar on-going challeng environ restrict narrow network
howev gross new win pbm sell season reflect
strength core busi model furthermor lap lost rx headwind
retail top-lin growth re-acceler believ well posit take advantag
growth gener specialti pharmaceut believ retail pbm
valu proposit mainten choic offer reson well market
believ continu win pbm share also help drive volum retail
competit high chang retail pharmaci pbm market highli
competit industri consolid chang retail pbm landscap
acquisit medco express script merger health solut
catalyst health solut walgreen allianc boot
combin consolid market share among largest compani pbm
may need price aggress retain custom impact profit
custom retent
macroeconom climat uncertain continu econom slowdown
would bode poorli client individu consum retail pharmaci
product pbm plan sponsor would suffer averag unemploy rate
along averag level consum spend purchas power would
decreas prescript drug util weak macroeconom outlook would also hurt
profit pbm client possibl decreas number cover live
organ govern entiti third-parti seek decreas
prescript drug cost seek increas substitut gener drug
brand drug normal benefici bottom line retail pharmaci
downward pressur reimburs rate pharmaci could start cut away
margin consolid among gener pharmaceut manufactur may squeez
pharmaci would difficult negoti reduc acquisit cost
strong focu feder state govern rein healthcar cost
healthcar financ reimburs rate subject chang variou polit
econom interest exert influenc regulatori environ
failur retain/win new pbm contact pbm contract provid healthcar servic
plan member typic durat three year mean pbm
client base renew given year inher risk exist inabl retain
contract renew also certain pbm client may tailor contract deviat
typic term may renegoti contract prior expir
medicar part regul risk particip medicar part
prescript drug program retail pharmaci realiz increas drug util
compress margin individu migrat higher margin plan
one howev medicar part busi could impact one sever
factor includ chang drug cost retire drug subsidi revis medicar
program requir reduct fund failur integr acquir medicar part
busi failur win new contract competit bid process
risk cvs/aet transact either wont close due regulatori
constraint integr deal may challeng expect
also risk invest commun sentiment transact may
incom statement model fiscal year end decemb mm
pharmaci retail
good sold
revenu
revenu
earn alloc particip secur
net loss attribut non-control interest
adjust incom continu oper
incom statement model fiscal year end decemb mm
adjust one-tim item
adj incom cont op ex amort
adjust dilut ep ex amort
net incom continu oper
net loss attribut non-control interest
prefer dividend net incom tax benefit
net incom attibut caremark
cog net revenu
oper expens net revenu
depreci amort
 total
incom statement model fiscal year end decemb mm
cog net revenu
oper expens net revenu
depreci amort
pharmaci total revenu
third parti pharmaci revenu
depreci amort
combin revenu
depreci amort
